Carregant...
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the survival of patients diagnosed with this disease. Bortezomib was the first proteasome inhibitor to be approved for the therapy of multiple myelom...
Guardat en:
| Publicat a: | Blood Lymphat Cancer |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6467339/ https://ncbi.nlm.nih.gov/pubmed/31360084 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BLCTT.S82444 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|